A study to investigate the pharmacokinetics, safety, and tolerability of AZD4144 in participants with severe renal impairment, end-stage kidney disease, and in healthy participants

Inclusion Criteria

• Healthy Matched Control Participants Only (Cohort 2):
• - Stable renal function (for example, no clinically significant change in an estimated glomerular filtration rate (eGFR) within 3 months or longer prior to study the Screening Visit), as determined by the investigator.
• - Have an eGFR of ≥ 90 milliliter/minute/1.73m2 (mL/min/1.73m2) as determined via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula without race.
• Renally Impaired Participants Only (Cohort 1)
• - Participants who have renal impairments.
• - Participants with severe renal impairment must have an eGFR ≥ 15 to < 30 mL/min/1.73m2 not on dialysis.
• - Cohort 1 should have at least 3 participants with eGFR ≤ 20 mL/min/1.73m2.
• Cohort 3
• - Participants with ESKD on IHD must have been on stable IHD for at least 3 months prior to Visit 1.
• - All renally impaired participants should be on stable standard of care for at least 4 weeks prior to Visit 1.
• All cohorts:
• - Body weight of at least 50 kilograms (kg) and body mass index (BMI) within the range ≥ 18 to ≤ 35 kg/m2, inclusive.
• - All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.